New Mexico Educational Retirement Board Grows Stake in Abbott Laboratories $ABT

New Mexico Educational Retirement Board grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 7.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 86,402 shares of the healthcare product maker’s stock after purchasing an additional 6,200 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Abbott Laboratories were worth $7,840,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares in the last quarter. United Bank lifted its position in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC boosted its stake in shares of Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its holdings in Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT opened at $108.29 on Friday. The company has a market capitalization of $187.38 billion, a P/E ratio of 35.05, a PEG ratio of 2.02 and a beta of 0.59. The company has a 50-day moving average of $104.43 and a 200-day moving average of $100.12. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ABT shares. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research note on Thursday, August 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. TD Cowen raised their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Finally, Wells Fargo & Company upped their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.